Acadia Pharmaceuticals Inc.（ACAD）の株式分析ACADAcadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, ACADIA Pharmaceuticals Inc is not a strong buy. The stock is trading at $19.73, which is significantly lower than the average analyst price target of $34, indicating potential upside. However, the stock's RSI is at 44.37, suggesting it is nearing oversold territory but not yet a strong buy signal. The recent negative news regarding the RADIANT trial, which missed its primary endpoint, has led to a 24.95% year-to-date decline, posing a significant risk to recovery.

10 analysts cover ACAD: 8 rate it Buy, 2 Hold and 0 Sell. The average price target is 31.17.